Chimeric Antigen Receptor T-cell based cellular therapies for cancer: An introduction and Indian perspective

被引:1
|
作者
Rathod, Reena J. [1 ]
Sukumaran, Reghu K. [2 ]
Kedia, Neelam [1 ]
Kumar, Jeevan [2 ]
Nair, Reena [2 ]
Chandy, Mammen [2 ]
Gandikota, Lakshmikanth [1 ]
Radhakrishnan, Vivek Sulekha [2 ]
机构
[1] Intas Pharmaceut, Cell & Gene Therapy Div, Ahmadabad, Gujarat, India
[2] Tata Med Ctr, Hematol Oncol & HCT, Kolkata, W Bengal, India
关键词
Chimeric antigen receptor; T-cell; CAR-T; cellular therapy; cancer; India; B-CELL; CD19; IMMUNOTHERAPY; EXPANSION; TISAGENLECLEUCEL; MALIGNANCIES; LYMPHOCYTES; IDEC-C2B8; ANTI-CD20; LYMPHOMA;
D O I
10.4103/ijc.ijc_433_21
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Using one's own immune system for curing cancer has been an active field of research in cancer biology and therapeutics. One such opportunity in cellular immunotherapy is adoptive cell transfers. With the recent approval of CAR-T therapy as a cancer treatment, a whole new paradigm of cancer treatment has opened-up, with a ray of hope for relapsed/refractory cancer patients. Despite promising clinical outcomes, the therapy is in its early phase and remains out of reach for most patients due to its high cost and logistic challenges. In India, these therapies are unavailable and further confounded by the economic challenges and a large population. In this review, we discuss various aspects of T-cell immunotherapies with a special focus on CAR-T in the Indian scenario. We touch upon the basic scientific aspects, mechanism of action, manufacturing, clinical aspects and commercial aspects of the CAR-Tcell therapies and its future worldwide and in India.
引用
收藏
页码:204 / 214
页数:11
相关论文
共 50 条
  • [31] HEALTH TECHNOLOGY ASSESSMENT FOR CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR CANCER IN EUROPE, US, AND CANADA
    Stothard, C.
    Brown, A.
    Ralston, S.
    Curry, A.
    Cork, D.
    Hollier-Hann, G.
    VALUE IN HEALTH, 2020, 23 : S468 - S468
  • [32] Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer
    Li, Feng
    Zhang, Tengfei
    Cao, Ling
    Zhang, Yi
    CURRENT STEM CELL RESEARCH & THERAPY, 2018, 13 (05) : 327 - 335
  • [33] Antigen Selection for Enhanced Affinity T-Cell Receptor-Based Cancer Therapies
    Hickman, Emma S.
    Lomax, Martine E.
    Jakobsen, Bent K.
    JOURNAL OF BIOMOLECULAR SCREENING, 2016, 21 (08) : 769 - 785
  • [34] Chimeric antigen receptor T cell therapies for multiple myeloma
    Wu, Chao
    Zhang, Lina
    Brockman, Qierra R.
    Zhan, Fenghuang
    Chen, Lijuan
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)
  • [35] Chimeric antigen receptor T cell therapies for multiple myeloma
    Chao Wu
    Lina Zhang
    Qierra R. Brockman
    Fenghuang Zhan
    Lijuan Chen
    Journal of Hematology & Oncology, 12
  • [36] Chimeric antigen receptor T-cell therapy for melanoma
    Razavi, Azadehsadat
    Keshavarz-Fathi, Mahsa
    Pawelek, John
    Rezaei, Nima
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2021, 17 (03) : 209 - 223
  • [37] Chimeric antigen receptor T-cell therapy for ALL
    Maude, Shannon L.
    Shpall, Elizabeth J.
    Grupp, Stephan A.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2014, : 559 - 564
  • [38] Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis
    Reinhardt, Bryanna
    Lee, Patrick
    Sasine, Joshua P. P.
    CELLS, 2023, 12 (04)
  • [39] Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma
    Ma, Kun
    Hu, Ping
    CANCERS, 2023, 15 (23)
  • [40] Chimeric antigen receptor T-cell therapy toxicities
    Greenbaum, Uri
    Kebriaei, Partow
    Srour, Samer A.
    Olson, Amanda
    Bashir, Qaiser
    Neelapu, Sattva S.
    Rezvani, Katayoun
    Shpall, Elizabeth J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (06) : 2414 - 2424